Trypanosoma cruzi has a structure that allows subdivision into six distinct genetic groups, called TcI to TcVI, with differences in terms of geographical distribution, biological properties and susceptibility to drugs. The correlation between parasitic genetic variability and clinical forms of Chagas disease (ChD) remains incompletely established. The predominance of DTUs (Genetic Groups) TcII and TcVI in several Brazilian regions, associated to both the domestic and wild cycle of ChD is well known. This project intends to verify the genotypes of the parasites present in 100 patients with ChD enrolled in Ribeirão Preto and to evaluate the existence of potential targets in the parasite genome in order to correlate the results with the clinical evolution of the patients from whom the parasites were isolated. In addition to genotyping, genomic screening of the parasites, isolated from the patients by blood culture, will be carried out to identify potential target genes, which serve as prognostic markers for human ChD. This objective will be achieved simultaneously to achieve the primary goal, that is, to equip the laboratory headed by Professor João Santana da Silva, researcher supervisor of the works referred to in this subproject, Department of Biochemistry and Immunology, FMRP- USP, of genotyping capability of T. cruzi for further use in other clinical application projects.
News published in Agência FAPESP Newsletter about the scholarship: